Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 May 2022 | Story Lunga Luthuli
East College - Eco Vehicles Team
Overall winners of the 2022 Eco-vehicle race, East College, hard at work to get their car ready for the race held at the Odeion parking lot on the Bloemfontein Campus.

For the first time, the University of the Free State’s 2022 Eco-vehicle race – held on the Bloemfontein Campus on 14 May 2022 – had students from all three campuses participating in the programme and race; a cup was awarded to the college with the best support.

Although the annual event did take place in 2021, only team members were allowed access to campus due to the COVID-19 pandemic and lockdown regulations, and therefore the race was streamed live. 

Karen Scheepers, Assistant Director: Student Life, said: “To have the students back on campus supporting their teams was incredible; this event will become bigger and better every year.”

With the Eco-vehicle race project, the UFS aims to use an innovative skills development approach that will enable students to develop basic knowledge and skills on sustainable energy.

This year, 130 undergraduate students enrolled for this co-curricular skills programme that runs for nine months and culminates in the Eco-vehicle race. A total of eight teams competed in the energy efficiency race, speed race, obstacle course race, and the main event – the endurance race. For the first time in the main event, the teams raced against each other for 18 laps. 

The winners of this year’s event were Central College (Akasia, Karee, Kagiso, Soetdoring, and Wag-’n-Bietjie residences) for Spirit Cup, South Campus took home the Pit Stop, North College won the Smart Lap, and South College won the Endurance Race. The overall winners of the Eco-vehicle race were East College (Legatum residence). 

The driver for East College, Lebakeng Motlotlo, said: “Even though I have always been part of the KovsieACT Committee in my residence, seeing that the focus this year was more on energy saving and saving resources, it pushed me to participate.”

Motlotlo believes the practice he and his team went through worked for them, as they were able to practise “how to turn, slow down around corners, and save energy”. 

“Our team was very dedicated and knew how to improvise when faced with challenges. As a small residence and most of us living off campus, the race taught us the importance of teamwork.” 

Motlotlo believes “initiatives such as the Eco-vehicle race are important, as we learn other skills outside of lectures, which we sometimes think are not important”.

Scheepers said the plan is to “grow the programme, motivate other universities to also invest in their students through this programme, and race to become a national and maybe an international event”.

“The programme adds value to the student experience to ensure that they do not only obtain a degree during their study period, but also undergo practical application of acquired knowledge and skills through real-life situations and meaningful learning encounters,” said Scheepers. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept